CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs) In Vitro CCR6 antagonist 1 (compound 1b, 50 μM, 3 h) blocks the CCL20-induced CD4 + T cell migration. ?\nCCR6 antagonist 1 (30 nM-300 μM, 20 min) inhibits miniGi recruitment to CCR6 induced by CCL20, and β-arrestin-1 recruitment to CCR6 and CCR5 by CCL20 and CCL5 (5 nM), respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Migration AssayCell Line: CCL20 (500 ng/mL)-induced CCR6 + CD4 + T cell Concentration: 0.5, 5, 50 μM Incubation Time: 3 h Result: Inhibited CCL20-induced cell migration at 50 μM. In Vivo CCR6 antagonist 1 (compound 1b, 1 mg/kg, s.c., twice daily for 3 days) alleviates TNBS-induced inflammatory responses in mice . ?\nCCR6 antagonist 1 (1 mg/kg, s.c., twice, before and after zymosan treatment) shows anti-inflammatory effects in Zymosan-induced peritonitis mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Murine model of colitis (5 mg/mouse TNBS-induced) Dosage: 1 mg/kg Administration: Subcutaneous injection (s.c.), twice daily for 3 days. Result: Improved mice general conditions, attenuated macroscopic injury and counteracted neutrophils infiltration, both in the colon and in lungs. Animal Model: Zymosan-induced peritonitis mice Dosage: 1 mg/kg Administration: Subcutaneous injection (s.c.), twice, before and after zymosan treatment Result: Significantly reduced the total protein content and myeloperoxidase activity in the peritoneal lavage. Form:Solid IC50& Target:CCR6